Fifty-two week data from the first of two Phase III studies of Madrigal Pharmaceuticals, Inc.’s THR beta agonist resmetirom in non-alcoholic steatohepatitis (NASH) confirm earlier results of hepatic fat reduction and suggest improvements in fibrosis and inflammation – the incremental dataset also helps build resmetirom’s chance to be the first approved drug therapy in NASH.
Increased hepatic fat, worsening fibrosis and inflammation are the three hallmark symptoms of the multi-factorial disease, which has been the target of many drug development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?